Natus Medical Inc (BABY) Receives Consensus Recommendation of “Hold” from Brokerages
Natus Medical Inc (NASDAQ:BABY) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $48.00.
A number of analysts have recently weighed in on the stock. Benchmark Co. reiterated a “buy” rating and set a $48.00 target price (down from $55.00) on shares of Natus Medical in a report on Monday, May 1st. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, April 28th. TheStreet downgraded shares of Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. Finally, Raymond James Financial, Inc. downgraded shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 2nd.
Shares of Natus Medical (NASDAQ:BABY) traded up 0.73% on Friday, reaching $34.40. The company had a trading volume of 653,620 shares. Natus Medical has a one year low of $31.61 and a one year high of $44.39. The company has a market capitalization of $1.12 billion, a PE ratio of 33.08 and a beta of 1.02. The company’s 50-day moving average is $37.80 and its 200-day moving average is $37.96.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, April 26th. The medical equipment provider reported $0.30 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.33 by $0.03. The firm had revenue of $124.70 million for the quarter, compared to analysts’ expectations of $122.45 million. Natus Medical had a return on equity of 13.24% and a net margin of 11.11%. The business’s revenue for the quarter was up 42.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 earnings per share. Equities research analysts predict that Natus Medical will post $1.68 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Natus Medical Inc (BABY) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/12/natus-medical-inc-baby-receives-consensus-recommendation-of-hold-from-brokerages.html.
A number of institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new position in Natus Medical during the first quarter worth about $110,000. Victory Capital Management Inc. increased its position in Natus Medical by 94.0% in the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 1,543 shares during the last quarter. State of Alaska Department of Revenue increased its position in Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 60 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new position in Natus Medical during the first quarter worth about $216,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in Natus Medical by 6.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,320 shares of the medical equipment provider’s stock worth $220,000 after buying an additional 384 shares during the last quarter. 80.27% of the stock is owned by institutional investors.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.